Find Therapeutics
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2020-05-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)SAD and MAD Study of FTX-101 in Healthy Male Subjects
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Find Therapeutics
- Target Recruit Count
- 49
- Registration Number
- NCT06617546
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
News
Find Therapeutics Doses First Subject in Phase I Trial of FTX-101 for Chronic Optic Neuropathy
Find Therapeutics initiated a Phase I clinical trial of FTX-101, a potential treatment for chronic optic neuropathy, after receiving FDA approval.